Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Alnylam Pharmaceuticals I...

    NASDAQ: ALNY · Real-Time Price · USD
    322.15
    -2.85 (-0.88%)
    At close: Jun 25, 2025, 3:59 PM
    321.94
    -0.07%
    After-hours: Jun 25, 2025, 04:40 PM EDT

    Alnylam Pharmaceuticals Statistics

    Share Statistics

    Alnylam Pharmaceuticals has 130.39M shares outstanding. The number of shares has increased by 2.83% in one year.

    Shares Outstanding

    n/a
    		 130.39M

    Shares Change (YoY)

    n/a
    		 2.83%

    Shares Change (QoQ)

    n/a
    		 0.85%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 124.67M

    Failed to Deliver (FTD) Shares

    n/a
    		 70

    FTD / Avg. Volume

    n/a
    		 0.01%

    Short Selling Information

    The latest short interest is 3.45M, so 2.66% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 3.45M

    Short % of Shares Out

    n/a
    		 2.66%

    Short % of Float

    n/a
    		 3.53%

    Short Ratio (days to cover)

    n/a
    		 3.23

    Valuation Ratios

    The PE ratio is -107.99 and the forward PE ratio is 171.1. Alnylam Pharmaceuticals's PEG ratio is 2.79.

    PE Ratio

    n/a
    		 -107.99

    Forward PE

    n/a
    		 171.1

    PS Ratio

    n/a
    		 13.36

    Forward PS

    n/a
    		 5.4

    PB Ratio

    n/a
    		 447.73

    P/FCF Ratio

    n/a
    		 -705.29

    PEG Ratio

    n/a
    		 2.79
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Alnylam Pharmaceuticals.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 2.78, with a Debt / Equity ratio of 19.32.

    Current Ratio

    n/a
    		 2.78

    Quick Ratio

    n/a
    		 2.71

    Debt / Equity

    n/a
    		 19.32

    Debt / EBITDA

    n/a
    		 -7.25

    Debt / FCF

    n/a
    		 -30.43

    Interest Coverage

    n/a
    		 -1.25

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $1,008,180.72

    Profits Per Employee

    n/a
    		 $-124,734.08

    Employee Count

    n/a
    		 2,230

    Asset Turnover

    n/a
    		 0.52

    Inventory Turnover

    n/a
    		 4.12

    Taxes

    Income Tax

    n/a
    		 -99.22M

    Effective Tax Rate

    n/a
    		 26.29%

    Stock Price Statistics

    The stock price has increased by 35.33% in the last 52 weeks. The beta is 0.21, so Alnylam Pharmaceuticals's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.21

    52-Week Price Change

    n/a
    		 35.33%

    50-Day Moving Average

    n/a
    		 278.39

    200-Day Moving Average

    n/a
    		 264.61

    Relative Strength Index (RSI)

    n/a
    		 72.31

    Average Volume (20 Days)

    n/a
    		 993,401

    Income Statement

    In the last 12 months, Alnylam Pharmaceuticals had revenue of 2.25B and earned -278.16M in profits. Earnings per share was -2.16.

    Revenue

    n/a
    		 2.25B

    Gross Profit

    n/a
    		 1.92B

    Operating Income

    n/a
    		 -176.88M

    Net Income

    n/a
    		 -278.16M

    EBITDA

    n/a
    		 -178.85M

    EBIT

    n/a
    		 -235.52M

    Earnings Per Share (EPS)

    n/a
    		 -2.16
    Full Income Statement

    Balance Sheet

    The company has 966.43M in cash and 1.3B in debt, giving a net cash position of -329.62M.

    Cash & Cash Equivalents

    n/a
    		 966.43M

    Total Debt

    n/a
    		 1.3B

    Net Cash

    n/a
    		 -329.62M

    Retained Earnings

    n/a
    		 n/a

    Total Assets

    n/a
    		 4.21B

    Working Capital

    n/a
    		 2.19B
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -8.31M and capital expenditures -34.28M, giving a free cash flow of -42.59M.

    Operating Cash Flow

    n/a
    		 -8.31M

    Capital Expenditures

    n/a
    		 -34.28M

    Free Cash Flow

    n/a
    		 -42.59M

    FCF Per Share

    n/a
    		 -0.33
    Full Cash Flow Statement

    Margins

    Gross margin is 85.62%, with operating and profit margins of -7.87% and -12.37%.

    Gross Margin

    n/a
    		 85.62%

    Operating Margin

    n/a
    		 -7.87%

    Pretax Margin

    n/a
    		 -16.79%

    Profit Margin

    n/a
    		 -12.37%

    EBITDA Margin

    n/a
    		 -7.95%

    EBIT Margin

    n/a
    		 -7.87%

    FCF Margin

    n/a
    		 -1.89%

    Dividends & Yields

    ALNY does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for ALNY is $330, which is 1.5% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $330

    Price Target Difference

    n/a
    		 1.5%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 24
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 4.03

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist